Licensing
Scil Proteins has signed an agreement with the university technology transfer body ipal GmbH and Charité University Hospital, Berlin, for the purchase of Tat Phage display technology.
Tat Phage display allows the precise selection of Affilin therapeutics with high affinity and selectivity for disease targets from Scil Proteins’ proprietary Affilin libraries. Financial terms were not disclosed.
Until now, Scil Proteins’ screening process was based on the Ribosome Display technology, accessed in 2006 in a cross-licensing deal with CAT/MedImmune. The combination of Tat Phage display with Ribosome Display enhances both the speed and reliability of the screening process.
“We are delighted to have secured exclusive rights to the use of these unique state of the art screening and selection techniques,” commented Dr. Ulrike Fiedler, CEO of Scil Proteins. “This further strengthens our competitive position for the Affilin therapeutics platform.”
Scil Proteins will use this combined screening capability to identify Affilin lead therapeutic candidates in the core indications of cancer and inflammation/infectious diseases.
The technology transfer body ipal GmbH is financed by its university partners and Investitionsbank Berlin (IBB), working on behalf of Charité-Universitätsmedizin, Robert-Koch-Institut, Deutsches Herzzentrum, as well as for the Paul-Ehrlich-Institut in Langen and the International University Bremen.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
